<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110066</url>
  </required_header>
  <id_info>
    <org_study_id>190580-0002</org_study_id>
    <nct_id>NCT05110066</nct_id>
  </id_info>
  <brief_title>BPA vs. PEA in CTEPH</brief_title>
  <acronym>GO-CTEPH</acronym>
  <official_title>Balloon Pulmonary anGiOplasty Versus Pulmonary Endarterectomy in Patients With Chronic ThromboEmbolic Pulmonary Hypertension: a Non-inferiority Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kerckhoff Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Utrecht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially&#xD;
      life-threatening progressive disease that evolves from unresolved pulmonary embolism. Gold&#xD;
      standard treatment for CTEPH is pulmonary endarterectomy (PEA) performed by skilled&#xD;
      cardio-thoracic surgeons.&#xD;
&#xD;
      Some patients may not be surgical candidates due to co-morbidities or because the vascular&#xD;
      lesions are too distal making them technically inoperable. In these patients, balloon&#xD;
      pulmonary angioplasty (BPA) has emerged as an effective treatment. In a subgroup of patients,&#xD;
      the distribution of vascular lesions makes it possible to perform either BPA or PEA. There&#xD;
      has never been a head-to head comparison of BPA with PEA. The aim of this study is therefore,&#xD;
      to evaluate if BPA is non-inferior to PEA in patients with (CTEPH) who are eligible for both&#xD;
      treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An investigator-initiated multicenter, prospective, randomized, controlled, open label,&#xD;
      non-inferiority trial. The study will randomize (1:1) 152 patients with CTEPH who are&#xD;
      eligible for both PEA and BPA. Patients will be screened for study inclusion at the local&#xD;
      CTEPH multidisciplinary team conference and eligibility for both PEA and BPA will be&#xD;
      confirmed by a central adjudication committee.&#xD;
&#xD;
      PEA or BPA will be completed within 6 months from randomization. Follow-up visit with right&#xD;
      heart catheterization will be completed at 4 months and 12 months after PEA or last BPA&#xD;
      session.&#xD;
&#xD;
      Primary end-point is change in pulmonary vascular resistance from baseline to 4 months and 12&#xD;
      months after PEA or the last BPA session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pulmonary vascular resistance</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Change in pulmonary vascular resistance from baseline to 4-months and 12-months after the procedure(s). Patients on medical treatments at baseline will remain on medical treatments until the assessment of the primary endpoint, and be taken off if hemodynamics permit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean pulmonary artery pressure</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Mean pulmonary artery pressure measured by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Cardiac index measured by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean right atrial pressure</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Right atrial pressure measured by right heart catheterization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minutes walking distance</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Six minutes walking distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Clinical worsening includes all-cause mortality, nonelective hospitalization for pulmonary artery hypertension, and disease progression (disease progression is defined as a reduction from baseline in the six minutes walking distance by 15% plus worsening functional class (except for patients already in Orld health organization functional class IV).)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal pro B-type natriuretic peptide</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>N-terminal pro B-type natriuretic peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by the &quot;Living with pulmonary hypertension questionnaire&quot;</measure>
    <time_frame>4 months and 12 months</time_frame>
    <description>Measured by the use of Living with pulmonary hypertension questionnaire (21 questions scored 0-5. Minimum score is 0 and maximum score is 105. Low score means high quality of life and a high score means a low quality of life).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peri-operative/peri-interventional complications</measure>
    <time_frame>30 days</time_frame>
    <description>Complications related to balloon pulmonary angioplasty and pulmonary endarterectomy will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Total length of hospital stay in both groups</measure>
    <time_frame>4 month</time_frame>
    <description>Time of hospital stay will be recorded</description>
  </other_outcome>
  <other_outcome>
    <measure>Median survival at 12 month</measure>
    <time_frame>12 months</time_frame>
    <description>Deaths will be recorded recorded and a median 12 month survival will be calculated.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">139</enrollment>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>BPA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Balloon pulmonary angioplasty. Typically 4-8 sessions are needed to treat the patient. The specific pre-planning protocol, choice of wires and balloons, the number of vessels treated per session, and the decision that no further BPA sessions are needed is at the discretion of the treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to PEA will undergo surgery within 4 months after randomization and optional run-in phase. Distality of the dissection plane is at the discretion of the operating physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary endarterectomy</intervention_name>
    <description>Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.</description>
    <arm_group_label>PEA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Balloon pulmonary angioplasty</intervention_name>
    <description>Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.</description>
    <arm_group_label>BPA group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with chronic thromboembolic pulmonary hypertension according to current&#xD;
             European society of cardiology/European Respiratory Society guidelines and eligible&#xD;
             for both pulmonary endarterectomy and ballon pulmonary angioplasty by decision at the&#xD;
             local multidisciplinary team conference and central adjudication committee&#xD;
&#xD;
          -  Written informed consent from the patient&#xD;
&#xD;
          -  Patient age &gt;17 and &lt;80 years&#xD;
&#xD;
          -  Able to understand and follow instructions and to participate in the entire study&#xD;
             period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;12 months&#xD;
&#xD;
          -  Co morbidities evaluated at the multidisciplinary team conference, that contributes&#xD;
             significantly to the patients pulmonary hypertension&#xD;
&#xD;
          -  Not possible to perform balloon pulmonary angioplasty or pulmonary endarterectomy&#xD;
             within 4 months after randomization.&#xD;
&#xD;
          -  Evaluated at multidisciplinary team conference that changes in pulmonary artery&#xD;
             hypertension targeted therapy between baseline and 4 months follow-up is inevitable*&#xD;
&#xD;
          -  Known pregnancy or positive urine Human chorionic gonadotropin screening test in&#xD;
             fertile women&#xD;
&#xD;
          -  Previous balloon pulmonary angioplasty or pulmonary endarterectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Lang, MD,Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harm Jan Bogaard, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marion Delcroix, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Post, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>St. Antonius Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregely Meszaros, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pulmonary Hypertension Association Europe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johanna Pepke-Zaba, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Papworth Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Wiedenroth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kerckhoff Klinik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asger Andersen, MD, ass.prof.</last_name>
    <phone>40138052</phone>
    <phone_ext>0045</phone_ext>
    <email>asger.andersen@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristina Laut Matzen, RN,PhD</last_name>
    <phone>+4521673903</phone>
    <email>krlaut@clin.au.dk</email>
  </overall_contact_backup>
  <reference>
    <citation>Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013 Feb;41(2):462-8. doi: 10.1183/09031936.00049312. Epub 2012 Jun 14. Review.</citation>
    <PMID>22700839</PMID>
  </reference>
  <reference>
    <citation>Gall H, Hoeper MM, Richter MJ, Cacheris W, Hinzmann B, Mayer E. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev. 2017 Mar 29;26(143). pii: 160121. doi: 10.1183/16000617.0121-2016. Print 2017 Mar 31. Review.</citation>
    <PMID>28356407</PMID>
  </reference>
  <reference>
    <citation>Gerges C, Gerges M, Friewald R, Fesler P, Dorfmüller P, Sharma S, Karlocai K, Skoro-Sajer N, Jakowitsch J, Moser B, Taghavi S, Klepetko W, Lang IM. Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension: Hemodynamic Phenotyping and Histomorphometric Assessment. Circulation. 2020 Feb 4;141(5):376-386. doi: 10.1161/CIRCULATIONAHA.119.041515. Epub 2020 Jan 3.</citation>
    <PMID>31896275</PMID>
  </reference>
  <reference>
    <citation>Delcroix M, Vonk Noordegraaf A, Fadel E, Lang I, Simonneau G, Naeije R. Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2013 Jan;41(1):224-32. doi: 10.1183/09031936.00047712. Epub 2012 Aug 16.</citation>
    <PMID>22903956</PMID>
  </reference>
  <reference>
    <citation>Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982 Feb;81(2):151-8.</citation>
    <PMID>7056079</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46(4):903-75. doi: 10.1183/13993003.01032-2015. Epub 2015 Aug 29. Erratum in: Eur Respir J. 2015 Dec;46(6):1855-6.</citation>
    <PMID>26318161</PMID>
  </reference>
  <reference>
    <citation>Jenkins D, Madani M, Fadel E, D'Armini AM, Mayer E. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017 Mar 15;26(143). pii: 160111. doi: 10.1183/16000617.0111-2016. Print 2017 Jan. Review.</citation>
    <PMID>28298388</PMID>
  </reference>
  <reference>
    <citation>Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D'Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jaïs X, Simonneau G. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011 Nov 1;124(18):1973-81. doi: 10.1161/CIRCULATIONAHA.110.015008. Epub 2011 Oct 3.</citation>
    <PMID>21969018</PMID>
  </reference>
  <reference>
    <citation>Lang I, Meyer BC, Ogo T, Matsubara H, Kurzyna M, Ghofrani HA, Mayer E, Brenot P. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017 Mar 29;26(143). pii: 160119. doi: 10.1183/16000617.0119-2016. Print 2017 Mar 31. Review. Erratum in: Eur Respir Rev. 2017 Jun 14;26(144):.</citation>
    <PMID>28356406</PMID>
  </reference>
  <reference>
    <citation>Delcroix M, Lang I, Pepke-Zaba J, Jansa P, D'Armini AM, Snijder R, Bresser P, Torbicki A, Mellemkjaer S, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Jaïs X, Ambroz D, Treacy C, Morsolini M, Jenkins D, Lindner J, Dartevelle P, Mayer E, Simonneau G. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry. Circulation. 2016 Mar 1;133(9):859-71. doi: 10.1161/CIRCULATIONAHA.115.016522. Epub 2016 Jan 29.</citation>
    <PMID>26826181</PMID>
  </reference>
  <reference>
    <citation>Khan MS, Amin E, Memon MM, Yamani N, Siddiqi TJ, Khan SU, Murad MH, Mookadam F, Figueredo VM, Doukky R, Benza RL, Krasuski RA. Meta-analysis of use of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2019 Sep 15;291:134-139. doi: 10.1016/j.ijcard.2019.02.051. Epub 2019 Feb 23.</citation>
    <PMID>30850238</PMID>
  </reference>
  <reference>
    <citation>Tanabe N, Kawakami T, Satoh T, Matsubara H, Nakanishi N, Ogino H, Tamura Y, Tsujino I, Ogawa A, Sakao S, Nishizaki M, Ishida K, Ichimura Y, Yoshida M, Tatsumi K. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. Respir Investig. 2018 Jul;56(4):332-341. doi: 10.1016/j.resinv.2018.03.004. Epub 2018 Jul 3.</citation>
    <PMID>30008295</PMID>
  </reference>
  <reference>
    <citation>Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D92-9. doi: 10.1016/j.jacc.2013.10.024. Review.</citation>
    <PMID>24355646</PMID>
  </reference>
  <reference>
    <citation>Mayer E, Jenkins D, Lindner J, D'Armini A, Kloek J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Dartevelle P. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011 Mar;141(3):702-10. doi: 10.1016/j.jtcvs.2010.11.024.</citation>
    <PMID>21335128</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

